{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2011"],"condition":["Adenocarcinoma of colon","Oncologic patients"],"disease":["Oncologic Patients","Adenocarcinoma Of Colon"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2528540"],"location":["Italy"],"study_start_month":["7"],"keyword":["ELOXATIN*INFUS 1FL 40ML 5MG/ML","AVASTIN*INFUS 1FL 400MG 16ML","FLUOROURACILE TEVA*IV 5G 100ML","LEDERFOLIN*INFUS 1FL 100MG","XELODA*120CPR RIV 500MG"],"repository":["ECRIN MDR"],"study_status":["Ongoing"],"additional_accession":[]},"is_claimable":false,"name":"Bevacizumab + Folfox4 or Xelox2 as first- line treatment in colorectal cancer. Randomized phase II study.","description":"Primary objectives: To estimate the effectiveness of the combination of Oxaliplatino and Capecitabine (XELOX-2) + bevacizumab measured in terms of objective response rate in non treaty advanced colorectal cancer treatment.","dates":{"creation":"2011-07-15"},"accession":"2528540","cross_references":{"EU Clinical Trials Register":["2010-022091-31"]}}